FR09C0037I2 - Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise - Google Patents

Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise

Info

Publication number
FR09C0037I2
FR09C0037I2 FR09C0037C FR09C0037C FR09C0037I2 FR 09C0037 I2 FR09C0037 I2 FR 09C0037I2 FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 I2 FR09C0037 I2 FR 09C0037I2
Authority
FR
France
Prior art keywords
japanese encephalitis
attenuated
vero cell
vaccine
encephalitis virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0037C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ Corp
Walter Reed Army Institute of Research
Original Assignee
CJ Corp
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Corp, Walter Reed Army Institute of Research filed Critical CJ Corp
Publication of FR09C0037I1 publication Critical patent/FR09C0037I1/fr
Application granted granted Critical
Publication of FR09C0037I2 publication Critical patent/FR09C0037I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR09C0037C 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise Active FR09C0037I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042001 1997-08-28
KR19970042002 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
FR09C0037I1 FR09C0037I1 (enrdf_load_html_response) 2009-09-25
FR09C0037I2 true FR09C0037I2 (fr) 2021-11-05

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0037C Active FR09C0037I2 (fr) 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise

Country Status (15)

Country Link
US (1) US6309650B1 (enrdf_load_html_response)
EP (2) EP1604685B1 (enrdf_load_html_response)
JP (1) JP4161017B2 (enrdf_load_html_response)
KR (1) KR100314404B1 (enrdf_load_html_response)
CN (1) CN1142271C (enrdf_load_html_response)
AU (1) AU748730B2 (enrdf_load_html_response)
CA (1) CA2301000C (enrdf_load_html_response)
DE (2) DE122009000037I2 (enrdf_load_html_response)
DK (2) DK1025209T3 (enrdf_load_html_response)
ES (2) ES2382946T3 (enrdf_load_html_response)
FR (1) FR09C0037I2 (enrdf_load_html_response)
MY (1) MY129773A (enrdf_load_html_response)
NL (1) NL300391I2 (enrdf_load_html_response)
NZ (1) NZ503522A (enrdf_load_html_response)
WO (1) WO1999011762A1 (enrdf_load_html_response)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
CN1618464A (zh) * 1998-10-05 2005-05-25 财团法人阪大微生物病研究会 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
DK1183332T3 (da) * 1999-04-22 2010-09-06 Us Agriculture Porcint Reproduktions- og Respirations Syndrom-vaccine baseret på isolere JA-142
AU4472801A (en) * 2000-04-07 2001-10-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese B encephalitis vaccine and process for producing the same
MXPA03011611A (es) * 2001-06-29 2004-07-01 Becton Dickinson Co Administracion intradermica de vacunas y agentes terapeuticos genicos a traves de microcanula.
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
DE602005015332D1 (de) * 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
US8591916B2 (en) * 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
KR101623994B1 (ko) * 2007-12-26 2016-05-24 기타사토 다이이치 산쿄 백신 가부시키가이샤 안정하게 장기간 보존할 수 있는 일본뇌염 백신의 제조방법 및 그 백신의 용도
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
KR101622738B1 (ko) * 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
ES2647882T3 (es) 2011-12-06 2017-12-27 Valneva Austria Gmbh Compuestos de aluminio para su uso en productos terapéuticos y vacunas
IN2013CH04135A (enrdf_load_html_response) * 2013-09-14 2015-08-14 Bharat Biotech Int Ltd
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
WO2017109225A1 (en) * 2015-12-23 2017-06-29 Valneva Austria Gmbh Zika virus vaccine
CN108697786B (zh) 2016-01-15 2022-05-27 Km生物医药股份公司 含有固定化病毒粒子的疫苗
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
SG11202001161YA (en) 2017-09-21 2020-03-30 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MY193736A (en) 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
AU2018375789B2 (en) 2017-11-30 2021-11-11 Takeda Vaccines, Inc. Method for inactivating Zika virus and related methods
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
WO2020045368A1 (ja) * 2018-08-27 2020-03-05 マイキャン・テクノロジーズ株式会社 不死化単球細胞および誘導細胞を用いた抗感染症薬，ワクチンなどの評価方法
US20230110516A1 (en) 2020-03-01 2023-04-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
IL296071A (en) 2020-03-01 2022-11-01 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4428231A1 (en) * 2022-04-20 2024-09-11 Korea National Institute of Health High-titer japanese encephalitis virus genotype 5 and use thereof
WO2024153686A1 (en) 2023-01-18 2024-07-25 Valneva Austria Gmbh Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
KR100314404B1 (ko) 2002-10-12
AU748730B2 (en) 2002-06-13
EP1604685A3 (en) 2006-07-05
CA2301000A1 (en) 1999-03-11
AU9004798A (en) 1999-03-22
EP1604685A2 (en) 2005-12-14
JP4161017B2 (ja) 2008-10-08
DK1604685T3 (da) 2012-06-18
FR09C0037I1 (enrdf_load_html_response) 2009-09-25
US6309650B1 (en) 2001-10-30
MY129773A (en) 2007-04-30
DE69837211D1 (de) 2007-04-12
WO1999011762A1 (en) 1999-03-11
NL300391I2 (nl) 2009-11-02
EP1025209A1 (en) 2000-08-09
JP2001514844A (ja) 2001-09-18
DE122009000037I2 (de) 2011-06-16
NZ503522A (en) 2001-06-29
KR19990023955A (ko) 1999-03-25
ES2382946T3 (es) 2012-06-14
DK1025209T3 (da) 2007-06-25
EP1025209B1 (en) 2007-02-28
CA2301000C (en) 2003-07-08
DE69837211T2 (de) 2007-12-06
EP1604685B1 (en) 2012-02-22
DE122009000037I1 (de) 2009-11-05
ES2281929T3 (es) 2007-10-01
CN1142271C (zh) 2004-03-17
CN1272879A (zh) 2000-11-08
NL300391I1 (nl) 2009-08-03

Similar Documents

Publication Publication Date Title
FR09C0037I2 (fr) Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise
GB2337755B (en) Virus vaccine
PL321966A1 (en) Vaccine against viral hepatitis of b type
BR9609258A (pt) Vacinas contra hepatite c
EP1112091A4 (en) FAST DEEP TEMPERATURE PRESSURE STERILIZATION AND VACCINE PRODUCTION
HUP0003911A3 (en) Treatment of neoplasms with viruses
NO961160L (no) Cykliske forbindelser, deres fremstilling og anvendelse
PL342847A1 (en) Compositions comprising viruses and methods for concentrating virus preparations
IL147969A0 (en) Peptides that block viral infectivity and methods of use thereof
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
DZ1706A1 (fr) Vaccin contre le virus de l'hepatite a.
NZ310055A (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
HUP9904171A3 (en) Immunogenic peptides of foot-and-mouth disease viruses
EP1113777A4 (en) NOVEL HEPATITIS C VIRUS PEPTIDES AND USES THEREOF
EP0769952A4 (en) VACCINE AGAINST THE INFECTIOUS CHICKEN ANEMIA VIRUS
HUP0101652A3 (en) Hepatitis vaccine
GB9702990D0 (en) Virus vaccine
GB9927353D0 (en) Virus preparation and use
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
HU0400424D0 (en) Hepatitis virus vaccines
GB9916702D0 (en) Virus vectors and preparations and their use
AU7276198A (en) Live virus vaccines to protect primates from hiv-1 infection and disease
GB9816773D0 (en) Virus vectors and expression elements,their preparation and use
AU6268199A (en) Live virus vaccines to protect primates from hiv-1 infection and disease